RT Journal Article
SR Electronic
T1 An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.10.21263376
DO 10.1101/2021.09.10.21263376
A1 Walker, Lauren E
A1 FitzGerald, Richard
A1 Saunders, Geoffrey
A1 Lyon, Rebecca
A1 Fisher, Michael
A1 Martin, Karen
A1 Eberhart, Izabela
A1 Woods, Christie
A1 Ewings, Sean
A1 Hale, Colin
A1 Rajoli, Rajith KR
A1 Else, Laura
A1 Dilly-Penchala, Sujan
A1 Amara, Alieu
A1 Lalloo, David G
A1 Jacobs, Michael
A1 Pertinez, Henry
A1 Hatchard, Parys
A1 Waugh, Robert
A1 Lawrence, Megan
A1 Johnson, Lucy
A1 Fines, Keira
A1 Reynolds, Helen
A1 Rowland, Timothy
A1 Crook, Rebecca
A1 Byrne, Kelly
A1 Mozgunov, Pavel
A1 Jaki, Thomas
A1 Khoo, Saye
A1 Owen, Andrew
A1 Griffiths, Gareth
A1 Fletcher, Thomas E
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/09/11/2021.09.10.21263376.abstract
AB Repurposing approved drugs may rapidly establish effective interventions during a public health crisis. This has yielded immunomodulatory treatments for severe COVID-19, but repurposed antivirals have not been successful to date because of redundancy of the target in vivo or suboptimal exposures at studied doses. Nitazoxanide is an FDA approved antiparasitic medicine, that physiologically-based pharmacokinetic (PBPK) modelling has indicated may provide antiviral concentrations across the dosing interval, when repurposed at higher than approved doses. Within the AGILE trial platform (NCT04746183) an open label, adaptive, phase 1 trial in healthy adult participants was undertaken with high dose nitazoxanide. Participants received 1500mg nitazoxanide orally twice-daily with food for 7 days. Primary outcomes were safety, tolerability, optimum dose and schedule. Intensive pharmacokinetic sampling was undertaken day 1 and 5 with Cmin sampling on day 3 and 7. Fourteen healthy participants were enrolled between 18th February and 11th May 2021. All 14 doses were completed by 10/14 participants. Nitazoxanide was safe and well tolerated with no significant adverse events. Moderate gastrointestinal disturbance (loose stools) occurred in 8 participants (57.1%), with urine and sclera discolouration in 12 (85.7%) and 9 (64.3%) participants, respectively, without clinically significant bilirubin elevation. This was self-limiting and resolved upon drug discontinuation. PBPK predictions were confirmed on day 1 but with underprediction at day 5. Median Cmin was above the in vitro target concentration on first dose and maintained throughout. Nitazoxanide administered at 1500mg BID with food was safe and well tolerated and a phase 1b/2a study is now being initiated in COVID-19 patients.Competing Interest StatementAO is Director of Tandem Nano Ltd. AO has received research funding from ViiV, Merck, Janssen and consultancy from Gilead, ViiV and Merck not related to the current paper. Ridgeback and GlaxoSmithKline have provided funding to the AGILE phase I/II platform to evaluate SARS-CoV-2 candidates independently of the current trial. GG has received funding from Janssen-Cilag, Astra Zeneca, Novartis, Astex, Roche, Heartflow, Celldex, BMS, BionTech, Cancer Research UK, NIHR, British Lung Foundation, Unitaid, GSK for unrelated academic clinical trials and programme funding. SK has received funding from Merck, ViiV, Janssen, Gilead for unrelated academic trials. No other conflicts are declared by the authors.Clinical TrialNCT04746183Funding StatementThis trial was funded by Unitaid as part of a supplement to project LONGEVITY in response to the SARS-CoV-2 pandemic. AO also acknowledges research funding from EPSRC (EP/R024804/1; EP/S012265/1), NIH (R01AI134091; R24AI118397), European Commission (761104). The authors also acknowledge funding from Wellcome Trust [221590/Z/20/Z] and Medical Research Council [MR/V028391/1] for the AGILE phase I/II platform trial.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and West Midlands Edgbaston Research Ethics Committee. The study was coordinated by the National Institute for Health Research (NIHR) Southampton Clinical Trials Unit with participants recruited into the NIHR Royal Liverpool and Broadgreen Clinical Research Facility (UK).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to restrictions containing information that could compromise the privacy of research participants